Biocartis Group, a molecular diagnostics company, has announced an extension of its partnership with ETPL with a new five-year strategic partnership, focused on the development of molecular diagnostic assays for Biocartis’ Idylla platform.
Partnership
The first assay selected for development under the partnership is a fully automated solid biopsy assay, aimed at supporting optimal therapy selection decisions for breast cancer patients.
Under the terms of the agreement, investment in development of the selected tests will be shared by both companies. Biocartis will be responsible for the commercialization of the tests under its own label, while ETPL will act as a development partner through Singapore's Diagnostics Development (DxD) Hub. Financial details have not been disclosed.
“By combining the expertise and network of ETPL and Biocartis, this partnership agreement has laid the foundation to bring more high performing Idylla assays to the market in a shorter timeframe,” stated Geert Maertens, chief scientific officer of Biocartis. “We are thrilled to work with ETPL for the development of our second5 breast cancer assay, this time aimed at supporting decisions for a rapidly growing number of targeted and hormone receptor therapies for breast cancer patients.”
“We are pleased to announce today an extension of our partnership with Biocartis, a global player in molecular diagnostics at the forefront of innovation,” added Sidney Yee, CEO of the DxD Hub, and executive vice-president of ETPL. “Over the years, Singapore's investment in research and development has established a strong base of technological capabilities and produced a pipeline of cancer biomarkers. ETPL's partnership with Biocartis is an excellent opportunity for us to accelerate the creation of diagnostics innovations that will serve the growing needs for early diagnosis of cancer, better patient monitoring and care, and lower health care costs.”